Anti-Asthmatics And COPD Drugs Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the anti-asthmatics and copd drugs market grown over the years?
The market for anti-asthmatics and COPD drugs has seen a significant growth in the recent past. The market size, which was $80.82 billion in 2024, is predicted to increase to $86.11 billion in 2025, recording a compound annual growth rate (CAGR) of 6.6%. Several factors contributed to the growth during the prior period, which include a surge in respiratory diseases, higher instances of tobacco smoking, impacts of global warming, aging population, emerging markets, advancements in drug discovery methods and enhancement in healthcare spending.
What Is the forecasted market size and growth rate for the anti-asthmatics and copd drugs market?
Predictions suggest a significant expansion in the anti-asthmatics and COPD drugs market in the forthcoming years. The market is anticipated to reach $107.01 billion by 2029, progressing at a 5.6% compound annual growth rate (CAGR). Several factors contribute to this projected surge during the forecast period including the rising popularity of e-cigarettes/vaping, escalating obesity rates, advanced technology, a large section of population yet undiagnosed, the application of anti-asthmatics and COPD medicines for treating COVID-19 patients, and the higher intake of fats. Key trends discerned in the forecast period involve the production of probiotic drugs for asthma, the creation of anti-il-5 medicines to broaden their commercial portfolio, the launch of groundbreaking products to fortify their market standing and maintain it amidst fierce competition, escalated investment in bioelectric medication development, focus on enhancing the total number of collaborations, offering tailored treatments, and generating combination medications for improved results and the development of biologics to leverage the escalating demand for them.
Get your anti-asthmatics and copd drugs market report here!
What are the major factors driving growth in the anti-asthmatics and copd drugs market?
The anti-asthmatics and COPD drugs market is influenced by controllable risk factors such as smoking, insufficient physical activity, and poor diet. Despite a global drop in smoking prevalence, developing nations like China, India, Indonesia, and Nigeria are experiencing an increase. For example, Indonesia is predicted to see a rise of 24 million tobacco smokers by 2025, and Nigeria a rise of 7 million, while China accounts for more than 40% of worldwide cigarette consumption. High-income countries, including the USA and Europe, have higher fat intake, including saturated fatty acids, a risk element for Asthma and COPD. The World Health Organization reveals that in developed nations, fats contribute to over 35% of the total energy requirement compared to less than 20% in low-income countries and below 25% in lower-middle-income nations.
What key areas define the segmentation of the global anti-asthmatics and copd drugs Market?
The anti-asthmatics and COPD drugs market covered in this report is segmented –
1) By Drug Class: Bronchodilators, Anti-Inflammatory Drugs, Monoclonal Antibodies, Combination Drugs
2) By Distribution Channel: Hospital Pharmacies, General Pharmacies, Online Retailers
3) By End User: Asthma Patients, COPD Patients
4) By Therapy: Preventive, Curative
5) By Route Of Administration: Oral, Inhaled, Intravenous, Subcutaneous
6) By Age Group: Below 5, 5-14, 15-60, Above 60
Subsegments:
1) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics (Short-Acting And Long-Acting), Methylxanthines
2) By Anti-Inflammatory Drugs: Corticosteroids (Inhaled And Systemic), Leukotriene Modifiers, Phosphodiesterase-4 Inhibitors
3) By Monoclonal Antibodies: Anti-IgE Antibodies, Anti-IL-5 Antibodies, Anti-IL-4 Or IL-13 Antibodies
4) By Combination Drugs: Combination Bronchodilator Inhalers (LABA + LAMA), Inhaled Corticosteroid + Long-Acting Beta-Agonist (ICS + LABA)
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3802&type=smp
What are the top market players propelling the growth of the anti-asthmatics and copd drugs industry?
Major companies operating in the anti-asthmatics and COPD drugs market include GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi S.A., Chiesi Farmaceutici S.p.A., Teva Pharmaceutical Industries Limited, Merck & Co. Inc., Sumitomo Dainippon Pharma Co. Ltd., China National Pharmaceutical Group Co. Ltd. (Sinopharm), Shanghai Acebright Pharmaceuticals Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, KYORIN Holdings Inc., Nichi-Iko Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Daewoong Pharmaceutical Co. Ltd, Shanghai Anovent Pharma, China Meheco Group Co. Ltd., Lupin Limited, ASGEN Pharmaceutical Co. Ltd, Abbott Laboratories, Pfizer, Vectura Group, Bristol Myers Squibb, Apotex Inc., EMS Pharma, Hypermarcas, Ache, Eurofarma, Bayer, Biolab Farmaceuticad, Cristalia, Libbs, Julphar, Neopharma, Adcock Ingram, Aspen Nigeria
What are the key trends shaping the future of the anti-asthmatics and copd drugs market?
Top enterprises engaged in the anti-asthmatics and COPD drugs market are focusing on product innovation such as fixed-dose combination (FDC) medicine, Indacaterol plus Mometasone, in an effort to boost market profitability. Delivered through the Breezhaler device, Indacaterol plus Mometasone is a daily FDC medicine created for the consistent treatment of asthma patients. As an illustration, Glenmark Pharmaceuticals, a pharmaceutical company based in the US, introduced a new fixed-dose combination (FDC) treatment, Indacaterol plus Mometasone, in India in June 2022. This new treatment is intended for individuals struggling with severe asthma. Marketed under the name Indamet, the treatment is available in three different versions, all of which contain a standard 150 mcg dose of Indacaterol and varying doses of Mometasone in strengths of 80 mcg, 160 mcg, and 320 mcg.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3802
What regions are dominating the anti-asthmatics and copd drugs market growth?
North America was the largest region in the anti-asthmatics and COPD drugs market in 2024. Middle East is expected to be the fastest-growing region in the global anti-asthmatics and COPD drugs market during the forecast period. The regions covered in the anti-asthmatics and COPD drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Anti-Viral Drug Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Implications And Growth
https://www.thebusinessresearchcompany.com/report/anti-viral-drug-therapy-market
COVID-19 Drug Associated APIs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/covid19-drug-associated-api-global-market-report
Hospital Acquired Infections Testing Kits Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
